Edward Tenthoff
Stock Analyst at Piper Sandler
(2.37)
# 2,547
Out of 4,955 analysts
178
Total ratings
41.04%
Success rate
-0.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $304 → $449 | $458.31 | -2.03% | 14 | Aug 1, 2025 | |
| NXTC NextCure | Maintains: Overweight | $36 → $15 | $5.13 | +192.40% | 5 | Jul 15, 2025 | |
| INO Inovio Pharmaceuticals | Initiates: Overweight | $5 | $1.85 | +170.27% | 1 | Jul 9, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Overweight | $105 | $53.07 | +97.85% | 7 | Jun 27, 2025 | |
| STRO Sutro Biopharma | Upgrades: Overweight | $2 | $0.86 | +131.35% | 7 | Jun 16, 2025 | |
| BMEA Biomea Fusion | Assumes: Overweight | $7 | $1.78 | +293.26% | 1 | Jun 3, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Overweight | $6 → $9 | $6.57 | +36.99% | 4 | May 29, 2025 | |
| ITOS iTeos Therapeutics | Maintains: Overweight | $16 → $12 | $10.21 | +17.53% | 1 | May 14, 2025 | |
| ARVN Arvinas | Reiterates: Overweight | $24 → $14 | $7.10 | +97.18% | 7 | May 2, 2025 | |
| IPSC Century Therapeutics | Maintains: Overweight | $4 → $2 | $0.55 | +266.97% | 8 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $48 | $11.97 | +301.00% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $24 | $15.01 | +59.89% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $78 | $35.63 | +118.92% | 4 | Dec 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $30 | $7.51 | +299.47% | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $45 | $20.20 | +122.77% | 11 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $115 → $69 | $26.89 | +156.60% | 12 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $65 | $9.42 | +590.02% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $1.54 | +1,068.83% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $7.17 | +388.15% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $3.50 | +471.43% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.39 | +115.83% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $3 | $0.81 | +271.10% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $4.43 | +261.17% | 3 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $1.13 | +430.97% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.64 | +204.88% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $56 | $42.35 | +32.23% | 4 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $224 → $248 | $10.32 | +2,303.10% | 5 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $2.80 | +3,114.29% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $180 | $17.94 | +903.34% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $18.21 | +141.63% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $7.03 | +426.32% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $2,246,640 → $651,200 | $1.96 | +33,224,389.80% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $660.97 | -46.44% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $135 | $1.40 | +9,542.86% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $394.36 | -18.10% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $37.86 | -4.91% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $1.16 | +2,055.17% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $1.74 | +8,520.69% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,380 | $0.47 | +293,517.02% | 1 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $591.01 | - | 11 | Feb 13, 2017 |
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Overweight
Price Target: $304 → $449
Current: $458.31
Upside: -2.03%
NextCure
Jul 15, 2025
Maintains: Overweight
Price Target: $36 → $15
Current: $5.13
Upside: +192.40%
Inovio Pharmaceuticals
Jul 9, 2025
Initiates: Overweight
Price Target: $5
Current: $1.85
Upside: +170.27%
CRISPR Therapeutics AG
Jun 27, 2025
Reiterates: Overweight
Price Target: $105
Current: $53.07
Upside: +97.85%
Sutro Biopharma
Jun 16, 2025
Upgrades: Overweight
Price Target: $2
Current: $0.86
Upside: +131.35%
Biomea Fusion
Jun 3, 2025
Assumes: Overweight
Price Target: $7
Current: $1.78
Upside: +293.26%
Fulcrum Therapeutics
May 29, 2025
Maintains: Overweight
Price Target: $6 → $9
Current: $6.57
Upside: +36.99%
iTeos Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $10.21
Upside: +17.53%
Arvinas
May 2, 2025
Reiterates: Overweight
Price Target: $24 → $14
Current: $7.10
Upside: +97.18%
Century Therapeutics
Mar 20, 2025
Maintains: Overweight
Price Target: $4 → $2
Current: $0.55
Upside: +266.97%
Feb 28, 2025
Maintains: Overweight
Price Target: $53 → $48
Current: $11.97
Upside: +301.00%
Feb 7, 2025
Reiterates: Overweight
Price Target: $15 → $24
Current: $15.01
Upside: +59.89%
Dec 30, 2024
Reiterates: Overweight
Price Target: $78
Current: $35.63
Upside: +118.92%
Dec 2, 2024
Upgrades: Overweight
Price Target: $20 → $30
Current: $7.51
Upside: +299.47%
Nov 27, 2024
Maintains: Overweight
Price Target: $62 → $45
Current: $20.20
Upside: +122.77%
Nov 18, 2024
Reiterates: Overweight
Price Target: $115 → $69
Current: $26.89
Upside: +156.60%
Nov 13, 2024
Maintains: Overweight
Price Target: $104 → $65
Current: $9.42
Upside: +590.02%
Nov 5, 2024
Initiates: Overweight
Price Target: $18
Current: $1.54
Upside: +1,068.83%
Oct 21, 2024
Initiates: Overweight
Price Target: $35
Current: $7.17
Upside: +388.15%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $3.50
Upside: +471.43%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.39
Upside: +115.83%
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $0.81
Upside: +271.10%
Jun 28, 2024
Reiterates: Overweight
Price Target: $16
Current: $4.43
Upside: +261.17%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $1.13
Upside: +430.97%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $1.64
Upside: +204.88%
Feb 27, 2024
Maintains: Overweight
Price Target: $39 → $56
Current: $42.35
Upside: +32.23%
Aug 14, 2023
Maintains: Overweight
Price Target: $224 → $248
Current: $10.32
Upside: +2,303.10%
Dec 12, 2022
Initiates: Overweight
Price Target: $90
Current: $2.80
Upside: +3,114.29%
Sep 7, 2022
Maintains: Overweight
Price Target: $140 → $180
Current: $17.94
Upside: +903.34%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $18.21
Upside: +141.63%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $7.03
Upside: +426.32%
May 13, 2022
Maintains: Overweight
Price Target: $2,246,640 → $651,200
Current: $1.96
Upside: +33,224,389.80%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $660.97
Upside: -46.44%
Sep 20, 2021
Maintains: Overweight
Price Target: $105 → $135
Current: $1.40
Upside: +9,542.86%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $394.36
Upside: -18.10%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $37.86
Upside: -4.91%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $1.16
Upside: +2,055.17%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $1.74
Upside: +8,520.69%
Dec 11, 2017
Initiates: Overweight
Price Target: $1,380
Current: $0.47
Upside: +293,517.02%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $591.01
Upside: -